A systematic review published in eClinicalMedicine suggests that some diabetes medications, specifically GLP-1 receptor agonists, could help reduce alcohol consumption and related health problems, especially in individuals with obesity. Studies showed that exenatide reduced alcohol consumption in people with obesity, while dulaglutide increased the likelihood of reduced alcohol consumption. However, further research is needed to incorporate these findings into clinical practice. The researchers also acknowledged limitations in the studies, such as heterogeneity in patient populations and incomplete safety profiles. Overall, integrating GLP-1 receptor agonists into patient care may reduce alcohol-related and liver disease-related morbidity and mortality.
Source link
GLP-1s may curb alcohol consumption in those with obesity
